Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

The Evaluation of Belimumab in Myasthenia Gravis (MG)

Phase 2

Completed

Conditions: Myasthaenia Gravis

Interventions: Biological: Belimumab
Other: Placebo

First Posted Date: 2011-11-29

Last Posted Date: 2017-02-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 40

Registration Number: NCT01480596

Locations: 🇮🇹
GSK Investigational Site, Milano, Lombardia, Italy

An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.

Phase 1

Completed

Conditions: Rhinitis, Allergic, Seasonal

Interventions: Drug: 2 ng GSK2445053
Drug: 20ng GSK2445053
Drug: Placebo
Drug: 400ng GSK2445053
Drug: 100ng GSK2445053
Drug: 1000ng GSK2445053
Drug: 4000ng GSK2445053
Drug: 200ng GSK2445053
Drug: 2000ng GSK2445053

First Posted Date: 2011-11-28

Last Posted Date: 2017-06-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 61

Registration Number: NCT01480271

Locations: 🇳🇱
GSK Investigational Site, Zuidlaren, Netherlands

Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue

Phase 3

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: GSK548470 300 mg tablet
Drug: ETV 0.5 mg capsule

First Posted Date: 2011-11-28

Last Posted Date: 2016-08-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 166

Registration Number: NCT01480284

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy

Phase 3

Terminated

Conditions: Muscular Dystrophies

Interventions: Drug: GSK2402968

First Posted Date: 2011-11-28

Last Posted Date: 2017-03-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 233

Registration Number: NCT01480245

Locations: 🇬🇧
GSK Investigational Site, Newcastle-upon-Tyne, United Kingdom

Study on the Incidence of Intussusception (IS) in Children Aged < 12 Months in Japan

Completed

Conditions: Intussusception

Interventions: Other: Data collection

First Posted Date: 2011-11-24

Last Posted Date: 2012-10-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 54

Registration Number: NCT01479491

Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects.

Phase 1

Completed

Conditions: Respiratory Disorders

Interventions: Drug: GSK1995057 single dose
Drug: Placebo

First Posted Date: 2011-11-22

Last Posted Date: 2017-06-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 56

Registration Number: NCT01476046

Locations: 🇬🇧
GSK Investigational Site, Harrow, Middlesex, United Kingdom

31P MRS Ischaemic Exercise Optimisation and COPD

Phase 1

Completed

Conditions: Atrophy, Muscular

Interventions: Other: MRI scan

First Posted Date: 2011-11-22

Last Posted Date: 2013-07-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 75

Registration Number: NCT01476072

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL)

Phase 1

Terminated

Conditions: Cancer

Interventions: Radiation: ML10

First Posted Date: 2011-11-22

Last Posted Date: 2013-07-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT01476085

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Study to Investigate the Effect of SB-705498 on Chronic Cough

Phase 2

Completed

Conditions: Rhinitis

Interventions: Drug: Placebo
Drug: SB-705498

First Posted Date: 2011-11-22

Last Posted Date: 2016-12-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 21

Registration Number: NCT01476098

Locations: 🇬🇧
GSK Investigational Site, Manchester, United Kingdom

Provoked Craving Relief Study by NRT

Phase 2

Completed

Conditions: Smoking Cessation

Interventions: Drug: nicotine

First Posted Date: 2011-11-22

Last Posted Date: 2013-09-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 120

Registration Number: NCT01476202

Locations: 🇺🇸
Central Kentucky Research Associates, Inc., Lexington, Kentucky, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy